Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · IEX Real-Time Price · USD

2.000

+0.070 (3.63%)

At close: May 2, 2024, 4:00 PM

2.010

+0.010 (0.50%)

After-hours: May 2, 2024, 7:19 PM EDT

Amylyx Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	170.92	63.25	50.38	13.07	3.09
Short-Term Investments	201.16	284.42	45.93	0	0
Cash & Cash Equivalents	372.08	347.66	96.31	13.07	3.09
Cash Growth	7.02%	261.00%	637.08%	322.71%	-
Receivables	40.05	15.31	0	0	0
Inventory	83.28	9.77	0	0	0
Other Current Assets	-30.75	9.39	8.64	0.57	0.11
Total Current Assets	464.67	382.13	104.95	13.64	3.2
Property, Plant & Equipment	6.41	8.14	0.47	0.15	0
Other Long-Term Assets	46.38	1.19	0.19	0.31	0.02
Total Long-Term Assets	52.79	9.32	0.66	0.47	0.02
Total Assets	517.45	391.45	105.61	14.1	3.22
Accounts Payable	22.06	6.26	4.37	3.61	2.2
Current Debt	2.26	2.04	0	0	0
Other Current Liabilities	57.72	38.31	13.02	3.71	2.33
Total Current Liabilities	82.04	46.61	17.4	7.33	4.53
Long-Term Debt	1.98	4.24	0	1.43	14.93
Other Long-Term Liabilities	0	0	0.04	0.02	1.44
Total Long-Term Liabilities	1.98	4.24	0.04	1.44	16.37
Total Liabilities	84.02	50.85	17.43	8.77	20.9
Total Debt	4.24	6.28	0	1.43	14.93
Debt Growth	-32.50%	-	-	-90.46%	-
Retained Earnings	-304.95	-354.22	-155.85	-67.91	-25.63
Comprehensive Income	0.2	-0.09	0.01	0	0
Shareholders' Equity	433.43	340.61	-151.17	-66.73	-25.36
Net Cash / Debt	367.84	341.39	96.31	11.64	-11.84
Net Cash / Debt Growth	7.75%	254.48%	727.31%	-	-
Net Cash Per Share	5.26	5.84	14.62	1.92	-2.01
Working Capital	382.62	335.52	87.56	6.31	-1.33
Book Value Per Share	6.45	5.82	-22.95	-10.98	-4.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).